

Electronic Acknowledgement Receipt

EFS ID:	3167380
Application Number:	10802013
International Application Number:	
Confirmation Number:	4932
Title of Invention:	Novel cyclosporins
First Named Inventor/Applicant Name:	Bruce F. Molino
Correspondence Address:	Michael L. Goldman Nixon Peabody LLP Clinton Square P.O. Box 31051 Rochester NY 14603-1051 US 5852631304 -
Filer:	Georgia Evans
Filer Authorized By:	
Attorney Docket Number:	20011/1331
Receipt Date:	17-APR-2008
Filing Date:	16-MAR-2004
Time Stamp:	14:31:45
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	yes
Payment Type	Deposit Account
Payment was successfully received in RAM	\$ 1270

RAM confirmation Number		9853			
Deposit Account		141138			
Authorized User					
File Listing:					
Document Number	Document Description	File Name	File Size(Bytes) /Message Digest	Multi Part /.zip	Pages (if appl.)
1	Foreign Reference	pat_EP_0484281_B2.PDF	1019201	no	28
			43e1d017ee1233db4a43eb088b02d94e2823e1e0		
Warnings:					
Information:					
2	NPL Documents	Prelog_Treatment_Psoriatic.PDF	235541	no	5
			2b9b9ec1ac154391fc3d56ee5d9f8a05a164b0c		
Warnings:					
Information:					
3	Extension of Time	20080417_Petition_for_Two_Month_Extension_of_Time_2809_1331.pdf	65275	no	1
			3a95168128469c20498a36a0d990c20189ea1016		
Warnings:					
Information:					
4		20080417_Amendment_-_2809_1331.pdf	373865	yes	93
			0e2008951431a749ba5458cae2d22542a56642ab		
	Multipart Description/PDF files in .zip description				
	Document Description		Start	End	
	Amendment Submitted/Entered with Filing of CPA/RCE		1	1	
	Claims		2	91	
	Applicant Arguments/Remarks Made in an Amendment		92	93	
Warnings:					
Information:					
5	Request for Continued Examination (RCE)	20080417_Request_for Continued_Examination_2809_1331.pdf	90939	no	1
			e8bf79a299cdf76eb0576843ba7b5c477d0df3dc2		
Warnings:					
This is not a USPTO supplied RCE SB30 form.					
Information:					
6	Information Disclosure Statement Letter	20080417_Supplemental_Information_Disclosure_Statement_for_2809_1331.pdf	55616	no	1
			7566a6d8896c11d69e4578ac039fe543581b01a0		

Warnings:					
Information:					
7	Information Disclosure Statement (IDS) Filed	20080417_PTO_SB_08A_for_Supplemental_IDS_28091331.pdf	111774 4d4b25ca4856b2a4865d72860a0a89722e5ca9d	no	2
Warnings:					
Information:					
This is not an USPTO supplied IDS fillable form					
8	NPL Documents	Bandera_Immunomodulators.PDF	1418517 af322f0a2deb60ce13549db1dc9f4786c16d4a6	no	17
Warnings:					
Information:					
9	NPL Documents	Bartz_Inhibition_of_Human.PDF	479430 79d4290c36c1be7764b0a2d52ed8c0fc4b08259	no	5
Warnings:					
Information:					
10	NPL Documents	DEB_025_ADIS_Database.PDF	79365 fda3ca2a909861252ba5d9a0b4de5a942b50a7	no	2
Warnings:					
Information:					
11	NPL Documents	Inoue_Combined_Interferon.PDF	402863 b3dbd63e0e35f3e241313a05b625eaf15b59d59e	no	6
Warnings:					
Information:					
12	NPL Documents	Merck_Common_Cold.PDF	129765 630be60a2b9d12502a45d210a682fe91b31e0b83	no	3
Warnings:					
Information:					
13	NPL Documents	Merck_Viral_Infections.PDF	192613 d203a944bdc93f9c2ba2cb4b0c1f03c45ae05456	no	4
Warnings:					
Information:					
14	NPL Documents	Nakagawa_Specific_Inhibition.PDF	485338 c903d84ec2b2c2049f91cfc2a9fb04899bcl1664a	no	6
Warnings:					
Information:					

15	NPL Documents	Paeshuyse_Potent_and_Selective.PDF	81002 <small>0816d7574d2265416829c9db772e7d7a9c4b6ec</small>	no	1
Warnings:					
Information:					
16	NPL Documents	Rosenwirth_Debio_025.PDF	179821 <small>39900124776e433d52270ad1023d3d5b3ca1d83</small>	no	2
Warnings:					
Information:					
17	Rule 130, 131 or 132 Affidavits	20080417_Molino_Supplemental_declaration_2809_1331.pdf	525815 <small>6cd47ad41a21e4c2255f02e44b2b437d29b54d4d0b</small>	no	3
Warnings:					
Information:					
18	Fee Worksheet (PTO-06)	fee-info.pdf	8272 <small>b895020be1a17275ee951e1e1e978596165b0c016</small>	no	2
Warnings:					
Information:					
Total Files Size (in bytes):			5935212		
<p>This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.</p> <p><u>New Applications Under 35 U.S.C. 111</u> If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.</p> <p><u>National Stage of an International Application under 35 U.S.C. 371</u> If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.</p> <p><u>New International Application Filed with the USPTO as a Receiving Office</u> If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.</p>					